A 77636 hydrochloride
Potent and selective dopamine D1-like receptor agonist (pEC50 values are 8.97 and < 5 for D1-like and D2-like receptors respectively). Displays anti-Parkinsonian activity following oral administration in vivo.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 365.9. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.73 mL||13.66 mL||27.33 mL|
|5 mM||0.55 mL||2.73 mL||5.47 mL|
|10 mM||0.27 mL||1.37 mL||2.73 mL|
|50 mM||0.05 mL||0.27 mL||0.55 mL|
References are publications that support the products' biological activity.
Acquas et al (1994) The potent and selective dopamine D1 receptor agonist A-77636 increases cortical and hippocampal acetylcholine release in the rat. Eur.J.Pharmacol. 260 85 PMID: 7957630
Kebabian et al (1992) A-77636: a potent and selective dopamine D1 receptor agonist with antiparkinsonian activity in marmosets. Eur.J.Pharmacol. 229 203 PMID: 1362704
Lewis et al (1998) Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J.Pharmacol.Exp.Ther. 286 345 PMID: 9655879
If you know of a relevant reference for A 77636 hydrochloride, please let us know.
View Related Products by Product Action
Keywords: A 77636 hydrochloride, supplier, Potent, selective, D1-like, agonists, Orally, active, Dopamine, D1, Receptors, D5, dopaminergic, A77636, hydrochloride, D1, and, D5, Receptors, D1, and, D5, Receptors, Tocris Bioscience
1 Citation for A 77636 hydrochloride
Citations are publications that use Tocris products. Selected citations for A 77636 hydrochloride include:
Guha et al (2012) Stimulation of the D5 dopamine receptor acidifies the lysosomal pH of retinal pigmented epithelial cells and decreases accumulation of autofluorescent photoreceptor debris. J Neurochem 122 823 PMID: 22639870
Do you know of a great paper that uses A 77636 hydrochloride from Tocris? If so please let us know.
Reviews for A 77636 hydrochloride
There are currently no reviews for this product. Be the first to review A 77636 hydrochloride and earn rewards!
Have you used A 77636 hydrochloride?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.